Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Teva Pharmaceutical Industries Limited (TEVA.TA)
Tel Aviv, IL
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.01% | -3.67% | +6.68% | -1.25% | +24.47% | +1.59% | +61.16% | +241.55% | +196.50% | -46.08% | +32.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+12.9% ★ Q1'26: +2.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+190.3% ★ Q1'26: +72.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.7% Q1'26: +3.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.5% Q1'26: +18.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.7% ★ Q1'26: +11.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.8% Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.08× Q1'26: 4.33× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 2 EPS Ana. |
Dec 2027 10 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 5 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.65B
est: 19.48B (+0.9%)
|
21.90B
est: 21.24B (+3.1%)
|
22.39B
est: 21.67B (+3.3%)
|
18.85B
est: 19.81B (-4.8%)
|
16.89B
est: 16.38B (+3.1%)
|
16.66B
est: 16.94B (-1.7%)
|
15.88B
est: 16.42B (-3.3%)
|
14.93B
est: 14.98B (-0.4%)
|
15.85B
est: 15.94B (-0.6%)
|
16.54B
est: 16.29B (+1.5%)
|
18.68B
est: 16.72B (+11.7%)
|
15.73B
15.59B – 15.87B
-5.9% YoY
|
16.38B
16.10B – 16.63B
+4.1% YoY
|
17.08B
16.86B – 17.29B
+4.3% YoY
|
17.44B
17.21B – 17.65B
+2.1% YoY
|
18.24B
18.00B – 18.46B
+4.6% YoY
|
| EBITDA |
6.34B
est: 575.29M (+1,002.2%)
|
6.45B
est: 627.34M (+927.4%)
|
-15.39B
est: 639.98M (-2,505.1%)
|
166.00M
est: 585.24M (-71.6%)
|
-27.00M
est: 483.70M (-105.6%)
|
-1.95B
est: 500.51M (-489.2%)
|
2.88B
est: 485.14M (+493.4%)
|
-925.00M
est: 442.43M (-309.1%)
|
1.56B
est: 470.80M (+230.9%)
|
777.00M
est: 1.46B (-46.7%)
|
3.42B
est: 1.50B (+128.4%)
|
1.41B
1.40B – 1.42B
-5.9% YoY
|
1.47B
1.44B – 1.49B
+4.1% YoY
|
1.53B
1.51B – 1.55B
+4.3% YoY
|
1.56B
1.54B – 1.58B
+2.1% YoY
|
1.63B
1.61B – 1.65B
+4.6% YoY
|
| EBIT |
2.62B
est: -989.21M (+365.1%)
|
1.37B
est: -1.08B (+227.0%)
|
-17.50B
est: -1.10B (-1,490.6%)
|
-1.68B
est: -1.01B (-66.5%)
|
-443.00M
est: -831.73M (+46.7%)
|
-3.51B
est: -860.64M (-307.3%)
|
1.55B
est: -834.21M (+285.7%)
|
-2.23B
est: -760.76M (-193.5%)
|
405.00M
est: -809.54M (+150.0%)
|
-282.00M
est: 265.56M (-206.2%)
|
2.34B
est: 272.61M (+756.9%)
|
256.45M
254.04M – 258.62M
-5.9% YoY
|
266.94M
262.49M – 271.07M
+4.1% YoY
|
278.43M
274.78M – 281.78M
+4.3% YoY
|
284.26M
280.53M – 287.69M
+2.1% YoY
|
297.25M
293.35M – 300.83M
+4.6% YoY
|
| Net Income |
1.59B
est: 6.10B (-74.0%)
|
329.00M
est: 5.69B (-94.2%)
|
-16.27B
est: 4.24B (-483.6%)
|
-2.15B
est: 3.50B (-161.4%)
|
-999.00M
est: 2.55B (-139.1%)
|
-3.99B
est: 2.90B (-237.7%)
|
417.00M
est: 2.94B (-85.8%)
|
-2.35B
est: 2.86B (-182.3%)
|
-559.00M
est: 2.71B (-120.6%)
|
-1.64B
est: 2.86B (-157.2%)
|
1.53B
est: 3.04B (-49.7%)
|
2.49B
2.45B – 2.53B
-18.1% YoY
|
3.42B
3.36B – 3.47B
+37.5% YoY
|
3.82B
3.76B – 3.88B
+11.7% YoY
|
4.12B
4.05B – 4.19B
+7.9% YoY
|
4.68B
4.60B – 4.76B
+13.5% YoY
|
| SGA |
4.72B
est: 4.35B (+8.3%)
|
5.10B
est: 4.75B (+7.3%)
|
4.99B
est: 4.84B (+2.9%)
|
4.21B
est: 4.43B (-4.9%)
|
3.81B
est: 3.66B (+4.0%)
|
3.67B
est: 3.79B (-3.1%)
|
3.53B
est: 3.67B (-3.9%)
|
3.45B
est: 3.35B (+2.9%)
|
3.50B
est: 3.56B (-1.8%)
|
3.70B
est: 3.62B (+2.3%)
|
3.97B
est: 3.71B (+7.0%)
|
3.49B
3.46B – 3.52B
-5.9% YoY
|
3.64B
3.58B – 3.69B
+4.1% YoY
|
3.79B
3.74B – 3.84B
+4.3% YoY
|
3.87B
3.82B – 3.92B
+2.1% YoY
|
4.05B
4.00B – 4.10B
+4.6% YoY
|
| EPS |
1.84
est: 5.39 (-65.9%)
|
0.07
est: 5.03 (-98.6%)
|
-16.01
est: 3.75 (-527.0%)
|
-2.11
est: 3.10 (-168.2%)
|
-0.92
est: 2.26 (-140.7%)
|
-3.64
est: 2.56 (-242.1%)
|
0.38
est: 2.60 (-85.4%)
|
-2.12
est: 2.53 (-183.9%)
|
-0.50
est: 2.40 (-120.9%)
|
-1.45
est: 2.46 (-158.9%)
|
1.23
est: 2.61 (-52.9%)
|
2.14
2.10 – 2.17
-18.1% YoY
|
2.94
2.89 – 2.99
+37.5% YoY
|
3.29
3.23 – 3.34
+11.7% YoY
|
3.55
3.49 – 3.60
+7.9% YoY
|
4.03
3.96 – 4.09
+13.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | TD Global Healthcare Leaders Index ETF TDOC.TO | 0.95% | 873.3K | 0.39% |
| 2 | Portfolio Building Block World Pharma and Biotech Index ETF PBPH | 0.89% | 8.46M | 0.13% |
| 3 | FlexShares ESG & Climate Developed Markets ex-US Core Index Fund FEDM | 0.57% | 438.9K | 0.16% |
| 4 | VictoryShares International Value Momentum ETF UIVM | 0.38% | 1.24M | 0.39% |
| 5 | Innovator International Developed Managed Floor ETF IFLR | 0.20% | 169.0K | 0.89% |
| 6 | Innovator International Developed Managed 10 Buffer ETF IBFR | 0.20% | 29.7K | 0.85% |
| 7 | iShares MSCI EAFE ETF Units IVE.AX | 0.18% | 743.0K | 0.32% |
| 8 | iShares MSCI EAFE Index ETF (CAD-Hedged) XIN.TO | 0.18% | 2.38M | 0.48% |
| 9 | Xtrackers US National Critical Technologies ETF CRTC | 0.17% | 233.7K | 0.35% |
| 10 | Goldman Sachs MarketBeta International Equity ETF GSID | 0.17% | 1.86M | 0.25% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard Francis | President, Chief Executive Officer & Director | 7M | male |
| Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer | 3M | male |
| Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer | 3M | — |
| Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise | 2M | female |
| Evan Lippman | Executive Vice President of Business Development | 2M | male |
| Matthew Shields | Executive Vice President of Global Operations | 2M | male |
| Richard Gordon Daniell | Executive Vice President of European Commercial | 2M | male |
| Mark Sabag | Executive Vice President of International Markets Commercial | 2M | male |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer | — | — |
| Kevin C. Mannix | Senior Vice President of Investor Relations | — | male |
| Christopher J. Stevo | Senior Vice President of Investor Relations & Competitive Intelligence | — | male |
| Placid Jover | Executive Vice President & CHRO | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TEVA.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
